Characteristics and clinical outcomes of COVID-19 patients with pulmonary disorders: A single-center, retrospective observational study

Wasim Jamal1,2 | Mohamad Y. Khatib1 | Mohammad Al Wraidat1 | Amna Ahmed1 | Dore C. Ananthegowda1 | Ahmed S. Mohamed1 | Asra Aroos1 | Prem Chandra3 | Mansoor Hameed2,4 | Muhammad Yousaf1,2 | Ahmed Al-Mohammed1 | Abdulqadir J. Nashwan1

1Department of Critical Care, Hazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), Doha, Qatar
2College of Medicine, Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar
3Academic Health System, Hamad Medical Corporation (HMC), Doha, Qatar
4Department of Medicine, Hamad General Hospital (HGH), Hamad Medical Corporation (HMC), Doha, Qatar

Correspondence
Abdulqadir J. Nashwan, Department of Critical Care, Hazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), P.O. Box 3050, Doha, Qatar.
Email: anashwan@hamad.qa

Funding Information
Hamad Medical Corporation, Grant/Award Number: MRC-01-20-532

Abstract
Introduction: Mortality rates and clinical characteristics of patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU) vary significantly.

Objectives: To describe the data of patients with pulmonary comorbidities who were admitted to the ICU with COVID-19 in Qatar in terms of demographic characteristics, coexisting conditions, imaging findings, and outcomes.

Methods: We conducted a retrospective study of the outcomes with regard to mortality and requirement of invasive ventilation, demographic characteristics, coexisting conditions, secondary infections, and imaging findings for critical care patients with COVID-19 in Qatar who had pulmonary comorbidities between March and June 2020.

Results: A total of 923 patients were included, 29 (3.14%) were found to have pulmonary disease. All these 29 patients’ respiratory disease was noted to be asthma. Among these, three patients (10.3%) died in the ICU within 28 days of ICU admission. They were all above 50 years old. Nineteen (66%) patients required intubation and mechanical ventilation. Twenty-one (72.4%) patients were males. The most common comorbidities included diabetes mellitus (55.1%) and hypertension (62%). Eighteen (62%) patients developed secondary infections in the ICU. Five (17.2%) patients developed renal impairment. Twenty (69%) patients received tocilizumab as part of their COVID-19 management, and out of these 16 (80%) patients developed a coinfection.

Conclusion: Patients with pulmonary disorders had higher mortality rates than other patients admitted to ICU during the same time frame with similar comorbidities; these patients require extra consideration and care to avoid disease progression and death.

KEYWORDS
asthma, coinfection, COVID-19, lung disease
INTRODUCTION

Since coronavirus disease 2019 (COVID-19) was discovered, which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It swiftly spread, resulting in an epidemic throughout the globe.\textsuperscript{1,2} While most patients have mild symptoms, some people experience acute respiratory distress syndrome (ARDS), possibly triggered by septic shock, multiorgan failure, cytokine storm, and blood vessels thrombosis.\textsuperscript{3,4} Disease outcomes varied across various regions and countries. While increasing age was considered a significant risk factor,\textsuperscript{3} comorbidities and coexisting medical conditions proved critical other factors in determining the severity of the disease and mortality outcomes.\textsuperscript{5-7} It subsequently and steadily became more relevant and essential to determine the effect of various diseases on COVID-19 outcomes. Over the course of the pandemic, evidence emerged that certain medical conditions could influence the outcomes more than the other disease. In relation to this, we focused on outcomes in COVID-19 patients who have known respiratory conditions—we conducted a retrospective study of the outcomes with regard to mortality and requirement of invasive ventilation, demographic characteristics, coexisting conditions, secondary infections, and imaging findings for critical care patients with COVID-19 in Qatar who had pulmonary comorbidities between March 21, 2020, and June 14, 2020.

MATERIALS AND METHODS

A retrospective observational study was conducted to describe the characteristics of COVID-19 patients who were admitted to the intensive care unit (ICU) in Hazm Mebaireek General Hospital (HMGH), a member of Hamad Medical Corporation (the primary healthcare provider in Qatar). The data were collected from the patients’ electronic medical records (Cerner). All consecutive 18 years or older patients with confirmed SARS-CoV-2 infection (laboratory) were admitted to the ICU in HMGH between March 21, 2020, and June 14, 2020, and had a confirmed diagnosis of a pulmonary disease documented in the patient medical record were included.

2.1 Statistical analysis

Data were analyzed using Microsoft Excel 2010 (Microsoft, Redmond, Washington) for Windows. All appropriate descriptive statistics were utilized to summarize and describe the study variables, such as frequencies and percentages.

RESULTS

From March 21 to June 14, 2020, a total of 923 patients were admitted with COVID-19 infection to the ICU in HMGH. Out of these patients, 29 (3.14\%) were found to have a pulmonary disease. All of their electronic records revealed that they had a previous diagnosis of asthma. Out of these, three (10.3\%) had a smoking history. Twenty-one (72.4\%) patients were males, and 8 (27.6\%) were females. The youngest patient was 33 years old, while the eldest one was 72 years old. The median age was 58 years. Twenty (69\%) patients required intubation and mechanical ventilation. The most common comorbidities included diabetes mellitus type 2 (55.1\%) and hypertension (62\%) (Table 1). Eighteen (62\%) patients developed a secondary infection in the ICU. Five patients (17.24\%) developed renal impairment. Nineteen (66\%) patients received tocilizumab for their COVID-19 management; 16 of them had developed an infection following the tocilizumab injection. Three patients (10.3\%) died within 28 days of ICU admission; they were all above 50 years old (Age 51, 57, and 69 Years). Out of three patients who died, two of them had hypertension (Table 2), and all three have developed secondary infections during their stay in the ICU (Figures 1 and 2).
4 | DISCUSSION

The mortality rates of patients with COVID-19 admitted to the ICU vary significantly in the published literature. Multiple factors explain the wide variability, such as the country's age structure, different thresholds for hospitalization, the robustness of a regional healthcare system, and availability of ICU beds, are various important factors.\(^8,9\) Comorbidities such as diabetes mellitus,\(^6\) hypertension,\(^10\) obesity, pulmonary (such as chronic obstructive pulmonary disease (COPD)), and cardio-cerebrovascular disease have been observed to be the more significant risk factors in patients with COVID-19.\(^11\) In our single-center, retrospective, observational study, we have presented various outcomes, including mortality and need for ventilation for COVID-19 patients with confirmed respiratory disease diagnoses who were admitted to HMGH (a designated COVID-19 facility in Qatar) from March to June 2020. Among the Gulf Cooperation Council (GCC) states, the infection rate is the second-highest (December 19, 2020) in Qatar (>10 000 cases per million population).\(^12\) However, the overall mortality rate remained low. Qatar initiated stringent control measures to limit the spread of infection earlier during the course of the pandemic. In the wake of the COVID-19 pandemic; Hamad Medical Corporation; the largest governmental healthcare provider in Qatar, ramped up a proactive plan to significantly expand hospital capacity, upskilling healthcare providers and involved reallocating existing resources and facilities and redeploying workforce as part of a strategy to expand critical care beds’ capacity rapidly.

Pulmonary disease has been identified to affect the outcomes of patients with COVID-19. In particular, COPD has been identified to be associated with poor outcomes.\(^14\) In our cohort of patients with known respiratory disease, 28-day mortality was 10.34%. In comparison, the total number of patients admitted to ICU during the same time frame was 923, out of which 43 patients died, giving overall 28-day mortality of 5.6%. This data are not matched and cannot conclude an association; however, we have observed higher mortality in our cohort of patients compared to all other patients admitted to ICU during the same time course and had similar comorbidities.

Interestingly, we note that in all of our 29 patients, the respiratory disease was asthma, and there were no patients who had COPD. Asthma, being the diagnosis in all our patients, is likely multifactorial. In the Gulf States, asthma has a higher prevalence. In addition, as the diagnosis was mostly clinical and lacked adequate objective assessment, our patients were likely overdiagnosed and overpresented. Furthermore, anecdotal data suggest that overdiagnosis of asthma universally is approximately 30%\(^6,16,17\). Asthma has also been noted as common comorbidity among patients admitted to the hospital with COVID-19. Garg et al reported that asthma was present in approximately 17% of the COVID-19 patients admitted to the hospital, making it the fourth most prevalent comorbidity (behind hypertension, obesity, and diabetes).\(^18\) Not a single patient had a previous diagnosis of COPD, which is surprising; however, a few factors that may explain it at least partially is the age structure of our cohort of patients. COPD is primarily diagnosed in older patients. Most of our patients were younger, and only three had a previous smoking history. In addition, as the diagnosis requires an objective assessment by spirometry, it is likely an underdiagnosed condition in our cohort of patients.

Although a multicenter retrospective study from the United States pertaining to hospitalized patients reported comparable mortality of 13.5% in asthmatic patients with COVID-19, it did not find any significant mortality difference between their asthmatics and nonasthmatics patients.\(^19\) However, our study only included ICU patients whose mortality is expected to be high. The lower mortality in our cohort of patients is likely multifactorial, including our patients' younger age.

As observed in other studies\(^8,18\), 44 diabetes mellitus (n = 18, 62%) and hypertension (n = 16, 55%) were also noted to be the commonest comorbidities among our patients (Table 3). Among the three patients in our study who died, in addition to asthma, two also had hypertension, and one had chronic kidney disease.

The need for invasive ventilation remained common throughout the pandemic. Numerous factors, including the healthcare system's robustness and variation in the threshold for ICU admission and intubation, can cause wide variation in the number of patients subjected to intubation and mechanical ventilation across various countries. In
our cohort of patients, 66% (n = 19) required invasive ventilation to manage their COVID-19 disease. The average duration of mechanical ventilation was 10 days. A study published in the Journal of the American Medical Association (JAMA) found a 47% intubation rate for patients who were admitted to the ICU.20 While presenting its outcomes related to COVID-19 in the New York City area, a case series published in JAMA found that 12.2% of hospitalized patients required intubation and ventilation.

In comparison, 14.2% of hospitalized patients required intubation and ventilation ICU care.21 However, in our study, the 66% intubation requirement is for ICU admissions. In another study published in JAMA, out of 21 patients admitted to ICU, 71% required mechanical ventilation.22

A systematic review and data analysis regarding hospital and ICU stay comprising of 52 studies, 46 studies from China published in September 2020 reported median ICU stay of COVID-19 patients for 8 days (IQR 5-13 days) in China and 7 days (IQR 4-11 days) outside of China.23

In our cohort of patients with respiratory comorbidities, the median ICU stay was 12 days, while the median duration of ventilation was 6 days. The median duration of ventilation for the patient who died was 9 days. A study published lately19 reported that although in COVID-19 patients with asthma as a comorbidity was significantly associated with a higher rate of endotracheal intubation, mechanical ventilation, and longer hospital length of stay, it was not associated with a higher rate of ICU admission, ARDS, or death among COVID-19 patients.

Severe acute kidney injury (AKI) is frequent in patients with COVID-19 and ARDS and is associated with high short-term mortality.24 In our cohort of patients with a known respiratory disease, 5/29 (17.24%) patients developed AKI. In the ICU settings, the development of AKI is multifactorial contributed by pathological processes, including hypotension, shock, ischemia, and the contribution from drugs’ adverse effects. In addition, the cytopathic effect of the virus is likely to have a role in contributing to worsening renal functions. A European multicenter retrospective observational study reported that among 211 patients, 55 (26%) developed Kidney Disease Improving Global Outcomes (KDIGO) stage 3 AKI within 7 days after ICU admission.24 A large multicenter prospective cohort study on the epidemiology of AKI in ICU patients in Beijing, China, showed that KDIGO stage 3 AKI accounted for 16% of critically ill patients.25 Findings in these studies were comparable to our observations, albeit our cohort of patients were selected based on known respiratory disease.

Eighteen (62%) of our patients developed a secondary infection (Table 3, Figure 3). A total of 10/18 of these patients had an infection with resistant organisms. All three patients who died developed a secondary infection during their ICU stay. Studies have so far shown an increased rate of secondary infection in patients admitted to hospital and ICU with COVID-19 disease. Zhang et al reported 22/38 (57.89%) patients developing secondary infection with COVID-19 in their multicenter cohort study in China 18, while Bogossian et al reported 33% multidrug-resistant bacteria (MDRB) acquisition during ICU stay for 72 patients.26 Viral sepsis contributing to immunosuppression and dysregulated immune response in the face of COVID-19 infection are

| TABLE 3 28-day mortality and invasive ventilation requirement of laboratory-confirmed COVID-19 patients with known pulmonary disease, by comorbidities, and smoking history |
|----------|----------|----------|----------|----------|
| DM (n = 18) | HTN (n = 16) | CAD (n = 3) | CKD | Smoking |
| Mortality n (%) | 0 (0%) | 2 (12.5%) | 0 (0%) | 1 (33.3%) | 0 (0%) |
| Requirement for vent n (%) | 12 (66.7%) | 12 (75%) | 2 (66.7%) | 3 (100%) | 2 (66.7%) |

FIGURE 3 Microorganisms-causing secondary infections

| Bacterial Infection | Fungal Infection | Both Bacterial and Fungal secondary Infection |
|---------------------|------------------|--------------------------------------------|
| 44%                 | 17%              | 39%                                        |
among the reasons making patients more susceptible to infections. Using invasive ventilation devices was also a risk factor for developing secondary infections. Drug-induced immunosuppression also plays a role in making patients susceptible to secondary infections. Pettit et al. reported significantly increased late-onset infections among those receiving tocilizumab, such as cytomegalovirus colitis. Kimmig et al. also reported a significantly higher rate of secondary infections and mortality in their cohort of patients who received tocilizumab.

Although our data cannot conclude a causal relation between tocilizumab and the development of secondary infections, also the development of secondary infection is multifactorial: in our cohort of patients, 16 (80%) patients who had tocilizumab developed a secondary infection, and 87% had it within 10 days of tocilizumab administration.

In our cohort of 29 patients, 28 were found to have an abnormal chest X-ray (CXR) while in the ICU. The most common pattern was bilateral infiltrates and patchy consolidation. One patient's CXR was clear, and the reason for admission to the ICU was hypotension secondary to diarrhea. In addition to patchy consolidation and bilateral infiltrates, one patient also had bilateral pleural effusion, which was likely secondary to coexistent heart failure. CXR findings in our study were consistent with other studies. Wong et al. reported that the common radiological findings in his retrospective study in Hong Kong include consolidation and ground glass opacities, with bilateral, peripheral, and lower zone distributions.

CONCLUSIONS
Respiratory disease has been identified to affect COVID-19 outcomes. In our single-center, retrospective, observational study, we observed higher mortality in our cohort of patients with respiratory disease in comparison to all other patients admitted to ICU during the same time course and had similar comorbidities. All our patients' respiratory disease was asthma. The data were not matched and cannot conclude an association between asthma and higher mortality; however, these patients require extra consideration and care to avoid disease progression and death. Further studies are encouraged to study this association. We also observed that more than half of our patients developed secondary infections, especially those who received tocilizumab. A significant number of patients developed secondary infections with resistant organisms. A high rate of secondary infections has been noted in other studies, and we reiterate the absolute importance of measures to prevent them, strict adherence to antimicrobial stewardship, and the use of tocilizumab in carefully selected patients.

FUNDING
This study was funded by the MRC IRB in Hamad Medical Corporation (MRC-01-20-532).

ACKNOWLEDGMENTS
The publication of this article was funded by the Qatar National Library.

REFERENCES
1. WHO. WHO Director-General’s remarks at the media briefing on 2019-nCoV on February 11, 2020. 2020.
2. Al Kuwari HM, Rahim HFA, Abu-Raddad LJ, et al. Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–April 18, 2020. BMJ Open. 2020;10(10):e040428.
3. Ye Q, Wang B, Mao J. Cytokine storm in COVID-19 and treatment. J Infect. 2020;80:607-613.
4. Mohamed MF, Al-Shokri SD, Shunnar KM, et al. Prevalence of venous thromboembolism in critically ill COVID-19 patients: systematic review and meta-analysis. Front Cardiovasc Med. 2020;7:1-12.
5. Nair AP, Al Masalamani MA, De Sanctis V, et al. Overdiagnosis of eosinophilia in patients with COVID-19: a controlled study. Acta Bio Medica Atenei Parmensis. 2020;91(4):e2020165.
6. Soliman AT, Prabhakaran Nair A, Al Masalamani MS, et al. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: a comparative study. Acta Bio Medica Atenei Parmensis. 2020;91(4):e2020164.
7. Khatib MY, Peediyakkal MZ, Elshafei MS, et al. Comparison of the clinical outcomes of non-invasive ventilation by helmet vs facemask in patients with acute respiratory distress syndrome. Medicine. 2021;100(4):e24443.
8. Sanyaelu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1-8.
9. Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.
10. Iqbal FM, De Sanctis V, Mustaq K, et al. Prevalence, clinical manifestations, and biochemical data of hypertensive versus normotensive symptomatic patients with COVID-19: a comparative study. Acta Bio Medica Atenei Parmensis. 2020;91(4):e2020163.
11. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12(7):6049-6057.
12. Alandijany TA, Faizo AA, Azhar E. Coronavirus disease of 2019 (COVID-19) in the Gulf cooperation council (GCC) countries: current status and management practices. J Infect Public Health. 2020;13:839-842.
13. Hu W, Dong M, Xiong M, et al. Clinical courses and outcomes of COVID-19 patients with chronic obstructive pulmonary disease during the COVID-19 epidemic in Hubei, China. Int J Chron Obstruct Pulmon Dis. 2020;15:2237-2248.
14. Pranata R, Soeroto A, Huang I, Lim M, Santos P. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. Int J Tuberc Lung Dis. 2020;24:838-843.
15. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92(10):1915-1921.
16. Aaron SD, Vandenheen KL, Boulet L-P, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ. 2008;179(11):1121-1131.
17. Lindensmith J, Morrison D, Deveau C, Hernandez P. Overdiagnosis of asthma in the community. Can Respir J. 2004;11(2):111-116.
18. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. Morb Mortal Wkly Rep. 2020;69(15):458-464.
19. Hussein MH, Toraih EA, Attia AS, et al. Asthma in COVID-19 patients: an extra chain fitting around the neck? Respir Med. 2020;175:106205.
20. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.
21. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. JAMA. 2020;323(20):2052-2059.
22. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020;323(16):1612-1614.
23. Rees EM, Nightingale ES, Jafari Y, et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med. 2020;18(1):1-22.
24. Chaibi K, Rao M, Pham T, et al. Severe acute kidney injury in patients with COVID-19 and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;202(9):1299-1301.
25. Jiang L, Zhu Y, Luo X, et al. Epidemiology of acute kidney injury in intensive care units in Beijing: the multi-center BAKIT study. BMC Nephrol. 2019;20(1):1-10.
26. Bogossian EG, Tacccone FS, Izzi A, et al. The acquisition of multidrug-resistant bacteria in patients admitted to COVID-19 intensive care units: a monocentric retrospective case control study. Microorganisms. 2020;8(11):1821.
27. Zhang H, Zhang Y, Wu J, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect. 2020;9(1):1958-1964.
28. Pettit NN, Nguyen CT, Mutlu GM, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol. 2021;93(3):1459-1464.
29. Khatib MY, Shaik KS, Ahmed AA, et al. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19. Clin Case Rep. 2021;9(1):148-152.
30. Kimmig LM, Wu D, Gold M, et al. Il-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Front Med. 2020;7:1-7.
31. Wong HYF, Lam HYS, Fong AH-T, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. Radiology. 2020;296(2):E72-E78.

How to cite this article: Jamal W, Khatib MY, Al Wraidat M, et al. Characteristics and clinical outcomes of COVID-19 patients with pulmonary disorders: A single-center, retrospective observational study. Health Sci Rep. 2022;5:e525. doi:10.1002/hsr2.525